LianBio announced that its Board of Directors unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of LianBio’s programs . After careful review and consideration, the Board unanimously concluded that the Proposal undervalues the Company and is not in the best interests of LianBio or its shareholders
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIAN:
- LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
- LianBio confirms receipt of unsolicited proposal from Concentra Biosciences
- LianBio price target lowered to $5 from $6 at BofA
- LianBio reports Q3 EPS (22c), consensus (30c)
- LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
